Introduction {#s1}
============

Genomic instability is a hallmark of cancer and is regulated by a balance between DNA damage and repair ([@B3]). The consequences of genomic instability include error-prone DNA synthesis, chromosome copy number variations and chromosomal structural aberrations ([@B81]; [@B61]) ([**Figure 1**](#f1){ref-type="fig"}). Conversely, unrepaired damage may cause transcription and replication arrest, inducing cell death and senescence ([@B74]).

![Genome instability and other consequences caused by mouse double minute 2 (MDM2). Oncogene p19 (ARF) interacts with MDM2 to prevent its function. MDM2 can inhibit both p53 and NBS1 to regulate many physiological processes or/and lead to genome instability, in which ATM plays a central phosphorylation regulatory role.](fphar-11-00631-g001){#f1}

In order to address the threat posed by genome changes, cells have evolved a kinase cascade signal transduction pathway called DNA damage response (DDR) ([@B69]). The initial step in active DDR is a rapid accumulation of DNA repair proteins to damage sites, which serve as a scaffold to recruit downstream factors ([@B156]). Mis-regulated DDR may increase accumulation of unrepaired DNA lesions and trigger aberrant cell proliferation, leading to malignance diseases ([@B80]).

Tumor suppressor p53 accumulates at DNA damage sites directly in both sequence-specific and non-sequence-specific manner to play a protective role in DDR ([@B94]; [@B98]) ([**Figure 1**](#f1){ref-type="fig"}). P53 deficiency leads to reduced repair activity and decreased cell survival after UV-induced DNA damage, indicating the participation of p53 in nucleotide excision repair (NER) ([@B155]). P53 also takes part in both global genome NER and transcription coupled NER through DNA polymerase δ and ϵ, respectively ([@B124]). Interaction between p53 with apyrimidinic endonuclease APE1/Ref-1 and the regulatory function of OGG1, MUTYH, and 3-methyladenine DNA glycosylase by p53 all indicate the function of p53 in base excision repair (BER). Among the two major pathways in double-strand break repair (DSBR), p53 interacts with both non-homologous end-joining (NHEJ) proteins and the promoter of homologous recombination (HR) protein RAD51 to regulate its expression ([@B188]).

The E3 ligase MDM2 (murine double minute 2) contains 491 amino acids and is a major negative regulator of p53 ([**Figure 1**](#f1){ref-type="fig"}). MDM2 controls activity, subcellular localization, and stability of p53 ([@B49]). Increased MDM2 expression is commonly observed in different types of cancers, indicating its oncogenic function ([@B49]). MDM2 interacts with large and diverse substrates through complex structures, post-translational modifications, and diverse isoforms to function as a significant hub in different signal pathways ([@B56]). The major role of p53 as a tumor suppressor relies on its transcriptional activity to regulate target genes in diverse biological pathways ([@B161]). MDM2 binds p53 directly through N-terminal transactivation domain to inhibit p53 transactivation ([@B127]; [@B135]). MDM2 also forms homodimers to ubiquitinate p53 leading to p53 proteasomal degradation ([@B70]; [@B90]). In this review, we highlight the specific regulation network of MDM2 in DDR and discuss the potential clinical applications of MDM2 antagonists and the perspective of developing novel combination strategies.

Genome Instability Induced by MDM2 {#s2}
==================================

As the negative regulator of p53, MDM2's function in cell survival versus cell death is complex and depends on the extent of DNA damage and the capacity of repair. The abnormal MDM2-p53 regulatory loop and its corresponding delayed DDR provide an additional layer for genomic instability control. The interaction of MDM2 with p53 and Mre11-Rad50-Nbs1 complex indicates MDM2 affects genomic instability in both p53-dependent and p53-independent manner.

MDM2 Affects Genomic Instability in p53-Dependent Manner {#s2_1}
--------------------------------------------------------

Given that MDM2 binds with p53 to inhibit its transactivation and that it induces p53 protein degradation, it is reasonable to assume that MDM2 regulates genome instability through p53 directly. Oncogene Myc activates p19 (ARF)-MDM2 pathway to coordinate p53-dependent checkpoint and apoptotic program ([@B201]; [@B50]). ARF interacts with MDM2 to guide its degradation and prevents negative feedback of p53/MDM2, thus preventing p53 degradation ([@B197]; [@B184]). A high level of MDM2 was identified in advanced stage breast ductal carcinomas and squamous cell carcinomas with wild-type p53. Overexpression of MDM2, and/or p53 deletion or mutation induced centrosome hyper-amplification and chromosome instability in these cancer cells ([@B29]). A study of lymphoma transformation showed that MDM2 overexpression in B cells led to a reduced susceptibility to p53-dependent apoptosis through inhibition of p53 and p21 ([@B181]). MDM2 transgenic mice also showed increased chromosome breaks, chromosome fusions, aneuploidy, and polyploidy ([@B106]). It has also been shown that p53 disruption by MDM2 overexpression activates the intra S-phase checkpoint to inhibit DNA replication origin firing, causing replication fork instability ([@B60]; [@B140]).

MDM2 Affects Genomic Instability in p53-Independent Manner {#s2_2}
----------------------------------------------------------

MDM2 also affects genomic instability independent of p53. It was found that mammary epithelial cells underwent multiple rounds of S phase without cell division to form increased polyploidy in response to MDM2 overexpression regardless of p53 expression level in mice ([@B105]). Mre11/Rad50/NBS1 (MRN) complex is a central sensor in DSBR. Mre11 and NBS1 mutant mice exhibit checkpoint defects and chromosomal instability ([@B159]). MDM2 associates with MRN complex through the direct interaction with NBS1 independent of p53, thus leads to recruitment of MDM2 at DNA damage sites with delayed DNA repair and compromised DNA integrity ([@B4]). Interaction of MDM2 with NBS1 inhibits DNA repair and leads to increased chromosome breaks and transformation efficiency in p53 deficient cells ([@B20]). With small molecular inhibitors targeting the interaction of p53 with MDM2, a p53 independent function of MDM2 in NBS1 regulation is found and worthy of considering in cancer drug design ([@B19]). In addition to binds NBS1, it has been reported that MDM2 ubiquitinates transcription factor HBP1 to facilitate its degradation, thus preventing the transcriptional inhibition role of HBP1 to its target genes to induce genomic instability like global DNA hypermethylation and histone hypermethylation ([@B28]).

Inhibitory Role of MDM2 in DNA Repair {#s3}
=====================================

MDM2 is regulated downstream of DNA damage by several mechanisms such as inactivation by post-translational modification and destruction p53-MDM2 interaction to relieve p53 inhibition. Increased p53 level leads to cell senescence, cell cycle arrest, and apoptosis. In the meanwhile, the interaction of MDM2 with DNA repair complex MRN exists and is independent of p53 state ([@B51]). The accumulated unrepaired DNA breaks further activate p53 and facilitate alterations such as chromosome translocations, gene fusions, increased micronuclei, and gene amplification, which are common causes of cancer malignancy ([@B130]; [@B23]). MDM2 is in turn transcriptionally regulated by p53 to form a feed-back loop to maintain cellular homeostasis under genetic stress.

Release of p53 After DNA Damage {#s3_1}
-------------------------------

The regulatory function of MDM2 on p53 after DNA damage is complex as it depends on the type of damage, p53 substrates, and various modifications on p53 and MDM2 proteins. The key step of p53 activation after DNA damage and other genetic stress results in the disruption of p53-MDM2 interaction and p53 release ([**Figure 2**](#f2){ref-type="fig"}). The inhibitory role of MDM2 on p53 includes blocking p53 transcriptional activation and regulating p53 protein level. Disruption of p53-MDM2 interaction alone is enough for p53 stabilization and activation even without DNA damage ([@B18]). The MDM2 binding sites in p53 amino terminus overlap with the binding sites in p53 that interact with the transcription machinery. MDM2 competes with transcription factors such as TFIID and TAFII31 for p53 binding to block p53 mediated transcription ([@B96]; [@B102]; [@B169]). A study also indicated that MDM2 directly repressed basal transcriptional machinery through its inhibitory domain ([@B170]). NEDD8 has a similar modification with ubiquitination, which can conjugate with p53 in a MDM2 dependent manner to repress p53 transcription ([@B191]). MDM2 also leads to a proteasomal degradation of p53. Moreover, expression of MDM2 significantly inhibits p53 accumulation after DNA damage. These results indicate a post-translational regulation under stress conditions ([@B70]; [@B90]).

![The regulation of p53-mouse double minute 2 (MDM2) axis after DNA damage. On the condition of DNA damage, both MDM2 auto-degradation and the disruption of p53-MDM2 interaction lead to stable and active p53. P53 is also phosphorylated at Ser15 and Ser37, resulting in the reduced p53-MDM2 interaction and increased transcription, activation and stability of p53 protein. MDM2-NBS1 association delays H2AX phosphorylation and inhibits DNA repair. MDM2 induces histones H2A and H2B monoubiquitylation, which affects chromatin structure and accessibility.](fphar-11-00631-g002){#f2}

Treatment with DNA damaging agents induce p53 phosphorylation at serine 15 and 37 which causes conformation changes in p53, resulting in reduced interaction of p53 with MDM2 ([@B150]). P53 acetylation was also reported to block p53-MDM2 interaction and which enable p53-dependent cell growth arrest and apoptosis under stress conditions ([@B167]). In addition, cells exhibit increased p53 phosphorylation by ATM, ATR, and other kinases after DNA damage with UV light and other agents, leading to p53 stabilization and enhanced DNA binding. The higher levels of p53 further activate transcription of downstream targets including MDM2 ([@B89]). As the repair process progresses, increased MDM2 decreases p53 expression and activity through the above mechanisms, forming a regulatory feedback loop to keep p53 and MDM2 protein at a basal level ([@B108]; [@B59]). The consequences of p53 regulation by MDM2 also depend on MDM2 activity. Low levels of MDM2 activity lead to p53 mono-ubiquitination and nuclear export whereas high levels promote p53 polyubiquitination and nuclear degradation ([@B95]).

Interaction of MDM2 With MRN Complex {#s3_2}
------------------------------------

Mre11/Rad50/Nbs1 (MRN) complex is essential in the maintenance of genome, meiosis, and telomere ([@B38]). Mre11 exhibits 3′--5′ double strand DNA exonuclease and endonuclease activity and joints two broken ends using their microhomology domains ([@B138]). Rad50 is a structural maintenance of chromosome (SMC) related protein, which functions in bridging DSB ends together to facilitate Mre11-dependent DSB end processing ([@B189]). NBS1 recognizes DSB ends and transduces cell cycle checkpoint signals through ATM-induced epigenetic modification. NBS1 also functions in chromosome remodeling in response to DSB ([@B189]). After ATM activation and HR repair initiation by MRN, nucleases such as CtIP, Exo1, and Dna2/BLM, cause DSB end resection to form 3′-overhangs, which are coated by RPA and Rad51 to facilitate strand exchange ([@B126]).

Although MDM2 promotes genomic instability and cancer development through the inhibition of p53, studies have also identified MDM2 function independent of p53 ([@B19]). MDM2 directly interacts with NBS1 through a 31-amino-acid region and is recruited to damage sites independent of p53 and ARF, a negative regulator of MDM2 ([@B4]) ([**Figure 2**](#f2){ref-type="fig"}). MDM2-NBS1 association delays H2AX and ATM-S/TQ phosphorylation and inhibits DNA repair ([@B20]). Additionally, MDM2 can bind other proteins involved in DNA replication or repair, such as DNA polymerase ϵ ([@B7]).

Other Regulatory Mechanisms of MDM2 Following DNA Damage {#s3_3}
--------------------------------------------------------

Mice with a hypomorphic allele in MDM2 gene revealed increased p53 transcriptional activation and apoptosis ([@B121]). Increased MDM2 protein level as a result of a single nucleotide polymorphism led to a decreased p53 signal transduction and higher tumor risk ([@B16]). All these evidences indicate that the amount of MDM2 protein dictates the physiological consequences of p53 activation. Further studies found that DNA damage induced MDM2 auto-degradation, which conversely stabilized and activated p53 ([@B157]). The half-life of MDM2 decreased after treatment with DNA damage agents neocarzinostatin (NCS), UV irradiation, and BCNU, while p53 stability and activation increased. This process is reversible and the half-life of MDM2 increases which corrects with unstable and inactive p53 when stress was eliminated ([@B158]).

Other studies demonstrated that MDM2 modulate DDR process through its association with and modification of chromatin, especially the promoter region of p53 target genes. Histone modification has long been known to affect transcription and DNA repair by influencing chromatin structure and accessibility, which is important for the recruitment of chromatin remodeling factors. MDM2 had been reported to interact with histones directly and induce monoubiquitylation of histones H2A and H2B *in vitro* and of H2B *in vivo* ([@B123]). In addition to that, the p53-MDM2 interaction may change p53 conformation and inhibit its binding to DNA. This function of MDM2 is mediated by its central acidic domain which binds to histone methyl transferase Suv39h1. The Suv39h1-MDM2 interaction restores p53 conformation allowing DNA binding of p53-MDM2-Suv39h1 complex ([@B37]). On the contrary, MDM2 was also reported to polyubiquitinate Suv39h1 at lysine 87 and to promote its degradation ([@B17]). This could be attributed to differences in cell context and experimental conditions ([@B187]). A p53-independent function of MDM2 in gene repression under stress conditions through chromatin modification warrants further investigation.

MDM2 Regulation in Response to DNA Damage {#s4}
=========================================

MDM2 binds N terminal of p53 to inhibit its transcription and promote its proteasomal degradation. MDM2 is also regulated by p53 to form an autoregulatory loop. Since MDM2 gene amplification and protein overexpression are found widely in human cancers, investigating the MDM2 related regulatory network under DNA damage is essential to understand its biological function as an oncogene and to identify novel targets for cancer therapy.

Regulation of MDM2 Expression {#s4_1}
-----------------------------

MDM2 gene can be transcribed from two independent promoters, P1 and P2. The P1 promoter transcribes from the first exon but without exon 2. P1 promoter carries out basal transcription and its activation does not need p53. P2 promoter is located within the first intron which includes two p53-binding sites and the transcriptional activation of P2 depends on p53 ([@B9]; [@B195]). Since the identification of increased expression of MDM2 variant in a range of human cancers and decreased expression in normal tissue in 1996, more than 72 kinds of MDM2 splice variants have been observed in both cancer and normal cells ([@B152]; [@B145]). Some of these variants are specifically spliced in response to DNA damage ([@B83]). However, their molecular mechanisms remain unknown.

The most common splice variants of MDM2 are MDM2-A (ALT2), MDM2-B (ALT1), and MDM2-C (ALT3). Compared to the full length MDM2 (MDM2-FL), which consists of 12 exons, MDM2-A lacks exon 4--9, MDM2-B lacks exon 4--11, and MDM2-C lacks exon 5--9. All these three variants lack p53 binding site at N terminal while they retain the C terminal RING domain, which facilitates their interaction with MDM2-FL ([@B77]). Based on such structural features, MDM2-A has been characterized to be a p53 activator. MDM2-A expression exhibits enhanced p53 activity and decreased transformation in p53-null setting ([@B177]). Activated p53/p21 pathway and increased cyclins D1 and E were discovered after MDM2-A expression ([@B146]). MDM2-B is frequently expressed in various cancer types including ovarian cancer, bladder cancer, astrocytic cancer, breast cancer, and giant cell tumors of bone ([@B152]; [@B111]; [@B55]; [@B104]). MDM2-B binds and sequesters full-length MDM2 in the cytoplasm and promotes p53 transcription by inhibiting interaction of MDM2-FL with p53 ([@B54]). Using a specific human MDM2-C antibody, high expression of endogenous MDM2-C was detected in cancer cell lines and in cancer tissues. Unlike MDM2-A and MDM2-B, MDM2-C had no effect on p53 degradation and transcription regulation but showed p53-independent transformation property ([@B133]).

Studies have identified a single nucleotide polymorphism (T/G SNP309) in MDM2 promoter region. This variant exhibit increased affinity toward the transcriptional activator Sp1, resulting in higher levels of MDM2 RNA and protein ([@B16]). In MDM2 SNP309 cells, p53 binds chromatin but cannot be activated ([@B6]). Overexpressed MDM2 with SNP309 is associated with increased risk of renal cancer development and worse patient prognosis in esophageal squamous cell carcinoma and B-cell chronic lymphocytic leukemia ([@B76]; [@B72]; [@B67]). MDM2 expression can be regulated by miRNAs induced by p53. Wild type p53 was identified in many multiple myeloma cases which induced the expression of miR-192, 215, and 194 leading to the downregulation of MDM2 ([@B139]).

Regulation of MDM2 Modification {#s4_2}
-------------------------------

The structural domains of MDM2 include (1) an N terminal lid domain (25--100 aa), a hydrophobic pocket controlling p53 binding, (2) a nuclear localization site (179--185 aa, NLS), (3) a nuclear export site (190--202 aa, NES), (4) a central acidic domain (243--301 aa), (5) a zinc finger domain (290--335 aa), and (6) a RING domain (432--491 aa), which is in charge of E3 ligase activity ([@B56]) ([**Figure 3**](#f3){ref-type="fig"}). MDM2 can be modified multisite phosphorylation/dephosphorylation, ubiquitination and SUMOylating ([**Figure 3**](#f3){ref-type="fig"}).

![Mouse double minute 2 (MDM2) regulation under DNA damage. The upper half part reflects the regulation of MDM2 expression, stabilization, modification, and location. All the three splice variants can interact with MDM2-FL, leading to the disruption of p53-MDM2 interaction and increased p53 activation. The single nucleotide polymorphism (T/G SNP309) exhibits increased MDM2 expression and p53 inhibition. P53 induces miR-192, 215, and 194 expression, which leads to MDM2 downregulation. The PCAF induced ubiquitination or auto-ubiquitination in MDM2 relate to its stability. ARF-induced MDM2 nucleus importation increases MDM2 mediated p53 response. PML plays the opposite role. MDM2 modification includes its ubiquitination, phosphorylation, and SUMOylation. The bottom half part indicates domains of MDM2, its phosphorylation and dephosphorylation sites, the related kinases or phosphatases, and the corresponding consequences. LID, Lid domain; NLS, nuclear localization site; NES, nuclear export site; Acidic Domain, central acidic domain; ZNF, zinc finger domain; RING, RING domain; ? (question mark), this function is still needed to be confirmed.](fphar-11-00631-g003){#f3}

### Phosphorylation {#s4_2_1}

MDM2 is frequently phosphorylated especially in the central acidic domain ([@B14]). Many kinases are reported to regulate MDM2 phosphorylation which controls its downstream activation or inhibition. The multiple phosphorylation sites within MDM2 can be divided into three groups (1) serine residues at 157, 166, 186, and 188 all of which are present near nuclear localization sites and nuclear export sites, (2) serine residues at 240, 242, 246, 253, 256, 260, 262, and 269 which is the phosphorylated cluster in the absence of any stress, and (3) serine 17, threonine 216, tyrosine 276, tyrosine 394, and serine at 395 and 407, all of which are phosphorylated under DNA damage stimulation ([@B119]).

The most important mediators in DDR are phosphatidylinositol 3-kinase-like protein kinase (PIKKs) family like ATM (ataxia telangiectasia mutated), ATR (ATM and Rad3-related), and DNA-PK (DNA-dependent protein kinase). DNA double strand breaks activate ATM and DNA-PK to induce downstream transduction. ATR is activated by the recruitment of RPA-coated single strand breaks with a partner protein ATRIP ([@B36]). Based on the presence of serine and threonine residues, which make up about 20% of all amino acids in MDM2 protein, MDM2 is a suitable phosphorylation substrate ([@B120]). The posttranslational modification of N-terminal region in both MDM2 and p53 can disrupt their interaction under cellular stress ([@B5]). The 16--24 residues of MDM2 were reported to form a lid crossing over p53 binding sites. This region functions in stabilizing MDM2 protein but weakly inhibits p53 binding ([@B118]). Interestingly, phosphorylated states in this region showed a significant influence in disrupting MDM2-p53 interaction. Following DNA damage, DNA-PK phosphorylates MDM2 at serine 17 and inhibits its interaction with p53, leading to p53 activation and G1 cell cycle arrest ([@B115]). ATM mediated substrate phosphorylation is an early response to DNA damage. MDM2 is phosphorylated by ATM at serine 395 (serine 394 in mouse) facilitating p53 release and accumulation in response to ionizing radiation and radiomimetic agents but not to UV radiation ([@B43]; [@B112]). Other residues (Ser386, Ser395, Ser407, Thr419, Ser425, and Ser429) located in C terminals of MDM2 have been identified to be phosphorylated by ATM after DNA damage in a redundant manner ([@B33]). The phosphorylation of these sites inhibits oligomerization of RING domain resulting in suppression of p53 poly-ubiquitination and degradation ([@B34]). Activation of a nuclear tyrosine kinase c-Abl is another response to ionizing radiation. This kinase is phosphorylated by ATM and is involved in cell cycle control ([@B10]; [@B22]; [@B149]). Following DNA damage, c-Abl binds MDM2 directly, phosphorylates MDM2 at tyrosine 394, and prevents p53 ubiquitination and its nuclear export. This c-Abl induced MDM2 tyrosine 394 phosphorylation triggered increased p53 transcription and decreased degradation leading to p53-mediated apoptosis ([@B153]; [@B65]). Additionally, tyrosine 276 was found to be phosphorylated by c-Abl in response to DNA damage *in vitro*. This modification enhanced MDM2 interaction with ARF with an increased expression of nucleolar MDM2 ([@B47]). These striking observations pointed out that c-Abl phosphorylation site is adjacent to ATM phosphorylation site indicating that ATM regulates MDM2 phosphorylation both in direct and indirect manner.

Recent studies indicate that many growth factors and cytokines are involved in cancer progression by regulating cell proliferation and apoptosis. The serine/threonine protein kinase Akt/PKB is an essential signal transducer downstream of phosphatidylinositol 3-kinase (PI3-kinase) ([@B93]). MDM2 can be phosphorylated at serine 166 and serine 186 by Akt/PKB which results nuclear translocation from cytoplasm ([@B113]). In addition to that, HER-2/neu-mediated Akt activation phosphorylates MDM2 to enhance p300 interaction and inhibits p19ARF interaction, resulting in increased degradation of p53 and blocked cytotoxic effect of DNA damage agents in cancer cells ([@B198]). Following stimulation with growth factors, PI3-kinase is activated and generates second messenger phosphatidylinositol (3,4,5)-trisphosphate PIP3 ([@B173]). A lipid phosphatase and tumor suppressor protein PTEN dephosphorylates PIP3 to disrupt this signal transduction. The mechanism is illustrated by the fact that high level of PTEN or PI3-K inhibitor dephosphorylates serine 166 and serine 186 of MDM2 and blocks its nuclear entry leading to an increased cellular p53 level and activity. Meanwhile, p53 further promotes PTEN expression to form a positive feedback loop in response to cellular stress. The PI3-K-Akt-MDM2 axis connects two important tumor suppressor PTEN and p53 to regulate cell survival, drug resistance and tumorigenesis ([@B113]; [@B116]; [@B114]; [@B131]). The protein kinase CK2 (CK2) is required for cell viability and cell cycle progression. CK2 is another protein kinase that phosphorylates MDM2 at serine 269 ([@B66]; [@B73]). The investigation of other kinases targeting MDM2 may further shed light on MDM2-p53 function.

It is equally important to consider MDM2 dephosphorylation mechanisms and impact on p53 regulation under cellular stress. Wild type p53-induced phosphatase 1 (Wip/PPM1D) can dephosphorylate MDM2 at serine 395, the same site that is phosphorylated by ATM, to inhibit MDM2 autophosphorylation and to stabilize MDM2 protein ([@B103]). Activation of p53 induces cyclin G1 transcription after DNA damage. Cyclin G1 interacts with a subunit of protein phosphatase 2A subunit (PP2A) to dephosphorylate MDM2 at tyrosine 216 site, promoting the ARF/MDM2 complex formation and p53 degradation ([@B87]; [@B120]). In another study, Cyclin G1/PP2A dephosphorylated MDM2 at both tyrosine 216 and serine 166 to activate it and to negatively regulate p53. However, the downstream functions of cyclin G1-p53 are complicated under various cellular stress. Exploring these issues should lead to a further understanding of p53-MDM2 regulation network ([@B132]).

### Ubiquitination {#s4_2_2}

During the ubiquitin conjugation modification process, the E3 ligase interacts specifically with target proteins to transfer ubiquitin. As a ubiquitin E3 ligase, MDM2 not only ubiquitinates p53 to guide its proteasomal degradation but also exhibits auto-ubiquitination function *via* C terminal RING finger domain ([@B57]; [@B75]). Multiple monoubiquitin sites exist in p53 which requires MDM2 isomerization ([@B92]). MDM2 auto-ubiquitination facilitates E2-conjugating enzymes accumulation and increased ubiquitination activity of MDM2 substrates, nevertheless the auto-ubiquitination is not required for MDM2 degradation ([@B78]; [@B142]). The choice between auto-ubiquitination and substrate-ubiquitination is regulated by other MDM2 posttranslational modifications including phosphorylation and SUMOylation ([@B120]). Other proteins are also found in the regulation of MDM2 ubiquitination. Transcription factor Yin Yang 1 (YY1) promotes p53 ubiquitination and degradation, which relays on enhanced p53-MDM2 interaction but not on its transcriptional activity ([@B160]).

### SUMOylation {#s4_2_3}

SUMO is a small ubiquitin-related modifier that modulates downstream gene expression in a ubiquitination-like pathway to influence protein stability, localization, DNA binding, and activation ([@B63]). Sumo conjugating enzyme Ubc9 mediated SUMOylation shows different consequences according to its substrates and the type of DNA damage. Residues 40--59 on MDM2 are responsible for Ubc9-MDM2 interaction and MDM2 SUMOylation, which is decreased following UV treatment ([@B25]). In response to radiation, the SUMOylation of MDM2 decreased in a dose-and time-dependent manner to enhance MDM2 auto-ubiquitination and to abrogate substrate-ubiquitination, resulting in increased p53 level ([@B24]). SUMOylation of MDM2 modulates MDM2 E3 ligase activity. SUMO-specific protease 2 (SENP2) removes SUMO modification from MDM2 and decrease p53 level ([@B35]).

Regulation of MDM2 Stabilization {#s4_3}
--------------------------------

MDM2 exhibits auto-ubiquitination function to promote protein degradation by ubiquitin-proteasome pathway in response to cellular stress or DNA damage ([@B30]). The half-life of MDM2 is short and the ubiquitin-related regulation balance shifts to MDM2 auto-ubiquitination and degradation to relieve p53 inhibition after exposure to these stressors ([@B157]). The histone acetyltransferase (HAT) p300-CBP-associated factor (PCAF) was reported to control MDM2 stability and p53 function through its ubiquitination activity ([@B97]).

Regulation of MDM2 Localization {#s4_4}
-------------------------------

The structural property of MDM2 enables it to shuttle between the nucleus and the cytoplasm. Subcellular location of MDM2 is important for regulating p53 transcriptional activity and degradation. In addition to the nuclear entry regulated by MDM2 phosphorylation, MDM2 mediated p53 nuclear export is also required for p53 degradation. MDM2 overexpression promotes p53 cytoplasmic location and this function relies on the RING finger domain in MDM2 and the NES signal in p53 ([@B21]; [@B62]). By contrast, the export protein CRM1 mediated p53 nuclear export did not cause p53 degradation indicating that the export of p53 is not essential for its degradation ([@B101]). The translocation of MDM2 into nucleus through ARF is needed for MDM2-mediated p53 response ([@B184]). Another tumor suppressor promyelocytic leukemia (PML) interacts with MDM2 and promotes p53 activity by enhancing the accumulation of p53 at PML nuclear bodies ([@B185]). Following DNA damage, PML localizes at nucleoli and sequesters MDM2 nucleolar localization to increase p53 stability ([@B12]).

MDM2 in Cancer Development {#s5}
==========================

The overexpression of MDM2 inhibits p53 activity. Highly expressed MDM2 attenuates p53 stress response and promotes cancer progression. Study in sarcomas identified MDM2 gene amplification together with a decreased growth control by p53 ([@B134]). MDM2 overexpression was also found in head and neck squamous carcinomas, indicating its contribution in cancer development ([@B172]). An efficient strategy would be to target MDM2 by improving p53 activity in some cancer types ([@B175]). Since MDM2 functions in p53 dependent and independent manner, studies of the roles of MDM2 in cancer development need to be considered in both situations.

P53 Dependent Oncogenic Function of MDM2 {#s5_1}
----------------------------------------

The most important oncogenic function of MDM2 comes from its binding with transcriptional activation domain and abrogating the antiproliferation effects of tumor suppressor protein p53 ([@B70]). MDM2 SNP309 is associated with high risk of cancer development, largely because of increased MDM2 protein level and inhibition of p53 activation ([@B15]). As a common feature of solid tumors, the hypoxia microenvironment is important in tumor growth, progression and metastatic potential. Hypoxia was reported to induce MDM2 up-regulation leading to a decreased p53 function ([@B196]). Alternative splice forms of MDM2 have been found in various human cancers, indicating diversified regulatory mode of MDM2 and its transcriptional variants ([@B83]). Both MDM2 overexpression and/or p53 mutation are exhibited in human cancers ([**Figure 4**](#f4){ref-type="fig"}). Over half of human cancers showed deficient or mutant p53 protein whereas the remaining harbor other kinds of alterations like MDM2 overexpression ([@B148]). Mice homozygous for p53 null allele developed spontaneous tumors with high probability, and most of the tumors were lymphomas ([@B48]; [@B79]; [@B141]). MDM2 plays an essential role in p53 regulation *in vivo*. The evidence came from MDM2 single knockout and MDM2/p53 double knockout mice. It was found that MDM2 loss triggered embryonic lethality in mice. In contrast, mice deficient in both MDM2 and p53 were rescued from this phenotype leading to normal development and survival. These results suggest the function of MDM2 in negative regulating p53 activity ([@B84]; [@B128])

![The function of mouse double minute 2 (MDM2) in cancer development. In p53 dependent manner, MDM2 SNP309, hypoxia microenvironment and alternative splice forms all induce MDM2 up-regulation, leading to p53 degradation or inactivation. Both lesions cooperation with other oncogenes like MDM2 overexpression and loss of tumor suppressor genes like p53 can promote cancer development. In p53 independent manner, FOXO3a is phosphorylated by ERK, becoming the ubiquitination target of MDM2. MDM2 binds E-cadherin to facilitate its ubiquitination and degradation. Meanwhile, MDM2 inhibits pRb function.](fphar-11-00631-g004){#f4}

The oncogenic feature of MDM2 only manifests in a background of pre-existing genetic lesions in cell-based studies. Because on the short half-life of MDM2 and the toxic cellular response to MDM2 overexpression, it is difficult to increase MDM2 expression to induce p53 inactivity and trigger transformation or tumorigenesis ([@B179]). Both lesions cooperate with other oncogenes and loss of tumor suppressor genes can promote tumorigenesis ([@B179]).

P53 Independent Oncogenic Function of MDM2 {#s5_2}
------------------------------------------

The p53 independent oncogenic function of MDM2 was identified in MDM2 transgenic mice in which mammary gland were prone to spontaneous cancer formation both in the presence or absence of p53 ([@B105]; [@B85]). One of the underlying mechanisms of this effect may be the MDM2-NBS1 interaction which leads to inhibition of DNA repair and increased transformation efficiency ([@B20]). Several MDM2 spliced variants have been found in different cancer types which are absent in normal tissues. All the variants can transform NIH3T3 cells. Moreover, some of them were unable to bind p53 but were still expressed in late-stage and high-grade ovarian and bladder cancer, suggesting a p53-independent oncogenic function ([@B152]). Considering the E3 ligase activity of MDM2, it is reasonable to assume that MDM2 ubiquitinates other targets involved in proliferation and tumorigenesis. The RAS--RAF--MEK--ERK--MAP kinase pathway is the most characterized signal transduction pathway regulating cell cycle arrest, cell proliferation, differentiation, and apoptosis. A wide range of mutations in these genes have been found in human cancers ([@B40]). ERK was reported to interact with and phosphorylate transcription factor FOXO3a at serine 294, 344, and 425. Phosphorylated FOXO3a is a ubiquitination target of MDM2 and is degraded by MDM2 mediated proteasome pathway in response to oncogenic growth factor signals ([@B194]). Southern blot and PCR methods have identified more frequent MDM2 gene amplification in metastatic or recurrent osteosarcomas than the corresponding primary cancer ([@B91]). This can be attributed to E-cadherin, an epithelial-to-mesenchymal transition associated cell-adhesion protein which interacts with MDM2 to facilitate its ubiquitination and degradation ([@B193]). Paradoxically, Slug (SNAI2), which belongs to Snail transcriptional repressor family, can be downregulated by MDM2 to enhance E-cadherin expression and repress cancer invasiveness ([@B182]). In addition, enhanced MDM2 expression correlates with increased vascular endothelial growth factor (VEGF) expression which may facilitate vascularity, metastasis, and tumor growth ([@B164]; [@B200]). Other than p53, another tumor suppressor gene retinoblastoma protein (pRb) is frequently mutated in human cancers. MDM2 was identified to interact with pRb directly to inhibit its cell cycle and apoptosis regulatory function ([@B190]).

MDM2 as a Target for Cancer Therapy {#s6}
===================================

The regulation functions of MDM2 on p53 focus on ubiquitinating p53 through the E3 ligase activity, blocking the binding of p53 to its target transcription sites and exporting p53 from nucleus, all suggests the necessity to design inhibitors targeting the interaction sites between MDM2 and p53. Considering the deficiency of single target drugs in therapeutic effect maintenance over time as well as the conduciveness to activate alternative signaling pathways facilitating drug resistance, dual or multi-targeting MDM2 inhibitors are emerging. Here, we review inhibitors which have been successfully developed for the clinical trials ([**Table 1**](#T1){ref-type="table"}).

###### 

Overview of small-molecules targeting mouse double minute 2 (MDM2) in clinical trials.

  Drug        Phases             NCT Number    Status                   Conditions
  ----------- ------------------ ------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RG7211      Phase 1            NCT00559533   Completed                Neoplasms
  RG7211      Phase 1            NCT00623870   Completed                Hematologic neoplasms
  RG7211      Phase 1            NCT01143740   Completed                Sarcoma
  RG7211      Phase 1            NCT01164033   Completed                Neoplasms
  RG7211      Phase 1            NCT01605526   Completed                Sarcoma
  RG7211      Phase 1            NCT01635296   Completed                Myelogenous leukemia, acute
  RG7211      Phase 1            NCT01677780   Completed                Myelogenous leukemia, chronic, neoplasms, myelogenous leukemia, acute
  RG7388      Phase 1            NCT01462175   Completed                Neoplasms
  RG7388      Phase 1            NCT01773408   Completed                Myelogenous leukemia, acute
  RG7388      Phase 1            NCT01901172   Completed                Neoplasms
  RG7388      Phase 3            NCT02545283   Recruiting               Leukemia, myeloid, acute
  RG7388      Phase 1\|phase 2   NCT02633059   Recruiting               Loss of chromosome 17p\|recurrent plasma cell myeloma
  RG7388      Phase 1\|phase 2   NCT02670044   Recruiting               Leukemia, myeloid, acute
  RG7388      Phase 1\|phase 2   NCT03135262   Active, not recruiting   Follicular lymphoma\|lymphoma, large B-cell, diffuse
  RG7388      Phase 1\|phase 2   NCT03158389   Recruiting               Glioblastoma, adult
  RG7388      Phase 1\|phase 2   NCT03337698   Recruiting               Carcinoma, non-small-cell lung
  RG7388      Phase 1            NCT03362723   Completed                Solid tumors
  RG7388      Phase 1\|phase 2   NCT03555149   Recruiting               Colorectal cancer
  RG7388      Phase 1\|phase 2   NCT03566485   Active, not recruiting   Stage III breast cancer\|stage IIIA breast cancer\|stage IIIB breast cancer\|stage IIIC breast cancer\|stage IV breast cancer\|estrogen receptor-positive\|HER2/Neu negative
  RG7388      Phase 1\|phase 2   NCT04029688   Recruiting               AML\|ALL\|neuroblastoma\|solid tumors
  RG7775      Phase 1            NCT02098967   Completed                Neoplasms, myelogenous leukemia, acute
  SAR405838   Phase 1            NCT01636479   Completed                Neoplasm malignant
  SAR405838   Phase 1            NCT01985191   Completed                Neoplasm malignant
  HDM201      Phase 1            NCT02143635   Active, not recruiting   Advanced solid and hematological TP53wt tumors
  HDM201      Phase 1\|phase 2   NCT02343172   Active, not recruiting   Liposarcoma
  HDM201      Phase 1            NCT02601378   Active, not recruiting   Uveal melanoma
  HDM201      Phase 1            NCT02780128   Recruiting               Neuroblastoma\|cancer
  HDM201      Phase 1            NCT02890069   Recruiting               Colorectal cancer, non-small cell lung carcinoma (adenocarcinoma), triple negative breast cancer, renal cell carcinoma
  HDM201      Phase 1            NCT03714958   Recruiting               Colorectal cancer\|advanced cancer\|metastatic cancer
  HDM201      Phase 1\|phase 2   NCT03760445   Recruiting               Leukemia, myeloid, acute
  HDM201      Phase 1            NCT03940352   Recruiting               AML\|high-risk MDS
  HDM201      Phase 2            NCT04116541   Not yet recruiting       Malignant solid tumor
  APG-115     Phase 1            NCT02935907   Recruiting               Patients with advanced solid tumor or lymphoma
  APG-115     Phase 1\|phase 2   NCT03611868   Recruiting               Unresectable or metastatic melanoma or advanced solid tumors
  APG-115     Phase 1\|phase 2   NCT03781986   Not yet recruiting       Malignant salivary gland cancer
  AMG-232     Phase 1            NCT01723020   Completed                Advanced malignancy\|advanced solid tumors\|cancer\|oncology\|oncology patients\|tumors\|glioblastoma\|multiple myeloma
  AMG-232     Phase 1            NCT02016729   Completed                Advanced Malignancy\|cancer\|oncology\|oncology Patients\|AML
  AMG-232     Phase 1\|phase 2   NCT02110355   Completed                Advanced malignancy\|advanced solid tumors\|cancer\|oncology\|oncology patients\|tumors\|melanoma
  AMG-232     Phase 1            NCT03031730   Recruiting               Hypercalcemia\|plasmacytoma\|recurrent plasma cell myeloma\|refractory plasma cell myeloma
  AMG-232     Phase 1            NCT03041688   Recruiting               AML\|recurrent AML\|refractory AML\|secondary AML
  AMG-232     Phase 1            NCT03107780   Recruiting               Glioblastoma\|gliosarcoma\|recurrent glioblastoma
  AMG-232     Phase 1            NCT03217266   Recruiting               Soft tissue sarcoma
  AMG-232     Phase 2            NCT03662126   Recruiting               PMF\|Post-PV-MF\|Post-ET-MF
  AMG-232     Phase 2            NCT03669965   Recruiting               Polycythemia vera
  AMG-232     Phase 2            NCT03787602   Recruiting               Merkel cell carcinoma
  AMG-232     Phase 1\|phase 2   NCT04113616   Recruiting               AML\|AML, secondary to MPN
  AMG-232     Phase 1            NCT04190550   Not yet recruiting       AML\|AML arising from previous MDS
  MK-8242     Phase 1            NCT01451437   Terminated               AML
  MK-8242     Phase 1            NCT01463696   Terminated               Solid tumors

AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; PMF, primary myelofibrosis; Post-PV-MF, post-polycythemia vera MF; Post-ET-MF, post-essential thrombocythemia MF; MPN, myeloproliferative neoplasms.

Inhibitors Targeting MDM2-p53 in Clinical Trials {#s6_1}
------------------------------------------------

Nutlins was a series of cis-imidazoline analogs identified to bind MDM2 in the p53-binding pocket, leading to cell cycle arrest and apoptosis in cancer cells, as well as growth inhibition of human tumor xenografts in nude mice ([@B174]). Several inhibitors targeting MDM2-p53 such as RG7112, RG7388, RG7775, SAR405838, HDM201, APG-115, AMG-232, and MK-8242 have recently been developed to treat human cancers with clinical trials. However, more clinical data is required to verify if these inhibitors can effectively block MDM2 or activate p53 and further improve the clinical efficacy in patients.

### RG7112 {#s6_1_1}

RG7112 was the first small-molecule MDM2 inhibitor to enter human clinical trials and which was derived from structural modification of Nutlin-3a ([@B100]). RG7112 was designed to target MDM2 in p53-binding pocket ([@B178]) and restored p53 activity inducing robust p21 expression and apoptosis in p53 wild-type glioblastomas cell ([@B176]). So far, seven clinical studies on RG7112 have been completed (<http://www.clinicaltrials.gov/>; NCT01677780, NCT01605526, NCT01143740, NCT01164033, NCT00559533, NCT00623870, NCT01677780). Study of NP25299 (NCT01164033) was an open-label, randomized, cross-over study in patients with solid tumors. It evaluated the effects of food on the pharmacokinetics of single oral doses of RG7112. This study included two parts: the first one comprised an initial single-dose, while the other comprised four different treatment schedules of increased doses. The results indicated that RG7112 was generally well tolerated with GI toxicities, the most common AEs, making it treatable with anti-emetics ([@B137]).

### RG7388 {#s6_1_2}

RG7388, a second-generation Nutlin, was developed to improve the potency and toxicity profile of earlier Nutlin. RG7388 induced p21 expression and effective cell cycle arrest in three cell lines MCF-7, U-2OS and SJSA-1, which proved the strong activation of p53 ([@B154]). RG7388 is currently undergoing several clinical examinations, including the only III clinical trial of MDM2 inhibitor (MIRROS/NCT02545283). The results of phase I clinical trial showed that RG7388 improved clinical outcomes by modulating p53 activity in AML patients with high levels of MDM2 expression ([@B144]). MIRROS is a randomized phase III clinical trial to evaluate the efficacy of RG7388 combined with cytarabine in the treatment of recurrent and refractory acute myeloid leukemia (AML). As of April 2019, the study has recruited approximately 90% of patient population and is still ongoing. If 80% of deaths are observed in p53-WT population of this study, an interim efficacy analysis can be obtained by 2020. MIRROS may obtain the first phase III clinical trial data of MDM2 inhibitors and provide a new treatment option for patients with AML ([@B129]).

### RG7775 {#s6_1_3}

RG7775 is an inactive pegylated prodrug of AP (idasanutlin), which cleaves the pegylated tail of esterases in the blood. AP is a potent and selective inhibitor of p53-MDM2 interaction to activate p53 pathway and associates with cell-cycle arrest and/or apoptosis. In a preclinical trial, intravenous (IV) RG7775 (RO6839921) showed anti-tumor effects in osteosarcoma and AML in immunocompromised mice model ([@B32]). In a phase I study (NCT02098967), RG7775 was investigated for its safety, tolerability, and pharmacokinetics in patients with advanced malignancies ([@B1]). The result showed that RG7775 had a safety profile comparable to oral idasanutlin.

### SAR405838 {#s6_1_4}

SAR405838 is an oral selective spirooxindole small molecule derivative antagonist of MDM2, which targets MDM2-p53 interaction ([@B183]). In the treatment of dedifferentiated liposarcoma cells, SAR405838 effectively stabilized p53, activated p53 pathway, block cell proliferation, promoted cell-cycle arrest and induced apoptosis ([@B13]). SAR405838 has been used in two clinical trials in cancer patients (NCT01636479, NCT01985191). Study of TED12318 (NCT01636479) was a phase I, open-label, dose-ranging, dose escalating, safety study administered orally in adult patients with advanced solid tumor. In this trial, 74 patients were treated with SAR405838 which showed best response in 56% patients with a 32% 3-month progression free rate. This study indicated that SAR405838 had an acceptable safety profile in patients with advanced solid tumors ([@B41]). Another clinical trial on SAR405838 was the study of TCD13388 (NCT01985191), which analyzed safety and efficacy of SAR405838 combined with pimasertib in cancer patients. In this study, 26 patients with locally advanced or metastatic solid tumors, who were documented to have wild-type p53 and RAS or RAF mutations, were enrolled in this study. The aim of this study was to explore maximum tolerated dose (MTD). Patient response was observed with SAR405838 at 200 or 300 mg QD plus pimasertib 60 mg QD or 45 mg BID. The most frequently occurring adverse events observed were diarrhoea (81%), blood creatine phosphokinase (77%), nausea (62%) and vomiting (62%). This study indicated that the safety profile of SAR405838 combined with pimasertib was consistent with the safety profiles of both the drugs ([@B44]).

### HDM201 {#s6_1_5}

HDM201 is a potent and selective small molecule that inhibits the interaction between MDM2 and p53, leading to tumor regression in preclinical models with both low and high dose regimen ([@B147]). HDM201 had a specific and effective killing effect on p53 wild-type cells with positive-ITD when used in combination with midotaline ([@B147]). HDM201 has been used in clinal trial (NCT02143635). NCT02143635 determined and evaluated a safe and tolerated dose of HDM201 in patients with advanced tumors with wild type p53. At the time of data cut-off (April 1, 2016), 74 patients received HDM201 (Reg 1 with 38 patients and Reg 2 with 36 patients still receiving treatment). The results showed that the common grade 3/4 adverse events (AEs) in both regimens (Reg 1 and Reg 2) were anemia (8%; 17%), neutropenia (26%; 14%), and thrombocytopenia (24%; 28%). Preliminary data indicated that hematological toxicity was delayed and dependent on regimen and that the Reg 1 regimen allows for higher cumulative dose ([@B82]).

### APG-115 {#s6_1_6}

APG-115 is a novel, orally active small-molecule MDM2 inhibitor. APG-115 restores p53 expression after binding with MDM2 and activates p53 mediated apoptosis in tumor cells with wild-type p53 ([@B2]). APG-115 has been used in clinical trials for treating solid tumor (NCT02935907), metastatic melanoma (NCT03611868), and salivary gland carcinoma (NCT03781986). Study NCT02935907 was a phase I study of the safety, pharmacokinetic and pharmacodynamic properties of orally administered APG-115 in patients with advanced solid tumors or lymphomas. Different dose levels (Including 10 mg, 20 mg, 50 mg, 100 mg, 200 mg and 300 mg) were tested in this study. The result showed the optimum dose of APG-115 to be 100 mg with no dose-limiting toxicities ([@B171]). In recent studies, APG-115 mediated the anti-tumor immunity of tumor microenvironment (TME). APG-115 activated p53 and p21 on bone marrow-derived macrophages *in vitro*, and reduced the number of immunosuppressive M2 macrophages by down-regulating c-Myc and c-Maf. In addition, APG-115 showed costimulatory activity in T cells and increased the expression of PD-L1 in tumor cells. This evidence suggests the combination of APG and immunotherapy may be a new anti-tumor regimen ([@B58]).

### AMG 232 {#s6_1_7}

AMG 232 is an investigational oral, selective MDM2 inhibitor that restores p53 tumor suppression by blocking MDM2-p53 interaction ([@B162]). The activity of AMG 232 and its effect on p53 signal were characterized in several preclinical tumor models. AMG 232 bind MDM2, strongly induced p53 activity, lead to cell cycle arrest and inhibit tumor cell proliferation ([@B27]). Several clinical trials of the AMG 232 such as NCT01723020, NCT02016729, NCT02110355, NCT03031730, NCT03041688, NCT03107780, and NCT03217266 have been ongoing to treat human cancers. NCT02016729 was an open-label phase I study that evaluated the safety, pharmacokinetics, and MTD of AMG 232. In this study, AMG 232 was administered in two regimens (arm 1 and arm 2). Patients were treated with AMG 232 at 60, 120, 240, 360, 480, or 960 mg as monotherapy once daily for 7 d every 2 weeks in arm 1 or at 60 mg combined with trametinib at 2 mg in arm 2. The results exhibited common treatment-related AEs included nausea (58%), diarrhea (56%), vomiting (33%), and decreased appetite (25%). However, the MTD of AMG 232 was not reached. Dose escalation was discontinued because of its unacceptable gastrointestinal AEs at higher doses ([@B52]).

### MK-8242 {#s6_1_8}

MK-8242 is a potent, small-molecule inhibitor which targets MDM2-p53 interaction ([@B86]). MK-8242 induced tumor regression of various solid tumor types and complete or partial response in most acute lymphoblastic leukemia xenografts ([@B86]). MK-8242 has been used in two Phase I clinical trials (NCT01451437 and NCT01463696). Study of NCT01451437 was a study of MK-8242 alone and in combination with cytarabine in adult participants with refractory or recurrent AML. In this study MK-8242 was administered at 30--250 mg (p.o;QD) or 120--250 mg (p.o;BID) for 7 d on/7 d off in a 28-d cycle and optimized regimen was administered at 210 or 300 mg (p.o;BID) for 7 on/14 off in 21-d cycle. Twenty-six patients were enrolled in this study, out of which 5 discontinued because of AEs and 7 patients died. This study showed the 7 on/14 off regimen had a more favorable safety profile than the 7 on/7 off regimen ([@B143]). NCT01463696 was aimed at evaluating the safety and pharmacokinetic profile of MK-8242 in patients with advanced solid tumors. In this study, drug dose was escalated to determine the MTD in part 1 and the MTD was confirmed and the recommended Phase 2 dose (RPTD) was established in part 2. Finally, 47 patients were enrolled in this study and treated with MK-8242 at eight level doses that ranged from 60 to 500 mg. The result showed that MK-8242 activated p53 pathway with an acceptable tolerability proﬁle at 400 mg (BID) ([@B180]).

MDM2-Based Multi-Target Inhibitors {#s6_2}
----------------------------------

Along with the development of MDM2 inhibitors, searching for multi-target inhibitors may be a new research direction. MDM2-based multi-target inhibitors could improve the efficacy and reduce the side effects ([@B42]). Dual inhibitors that have been reported to be co-inhibit with MDM2 include MDM4, NF-κB, histone deacetylases (HDAC), translocator protein (TSPO), XIAP, and integrins ([@B117]; [@B39]; [@B68]; [@B151]; [@B64]; [@B122]), which achieved excellent *in vitro* and *in vivo* antitumor potency. Considering MDM2 and MDM4 dual inhibitors had been well reviewed in the recent literature ([@B168]; [@B53]), we summarize other dual inhibitors.

### Dual Inhibitors of MDM2 and NF-κB {#s6_2_1}

Nuclear transcription factor (NF-κB) is a class of key nuclear transcription factors exist in the cytoplasm of almost all types cells in the form of homologous or heterodime. NF-κB family includes five DNA-binding proteins that are usually overexpressed in mammalian cancer cell ([@B136]). Previous studies found that NF-κB inhibit p53 stability by directly up-regulating MDM2 ([@B46]). The cross-talk between p53 and NF-κB showed that simultaneous activation of p53 and inhibition of NF-κB would provide a synergistic effect on anti-tumor activity. Zhang et al. designed a series of pyrrolo\[3,4-c\]pyrazole derivatives and synthesized as the first-in-class inhibitors for both p53-MDM2 interaction and NF-κB. These compounds effective targeted p53-MDM2 interaction and inhibit cell growth in A549 xenograft model ([@B199]). In addition, dual-target inhibitors enhanced the anti-tumor effect of radiotherapy in pancreatic cancer ([@B151]).

### Dual Inhibitors of MDM2 and HDAC {#s6_2_2}

Histone deacetylase (HDAC) is a kind of epigenetic enzyme plays an important role in the regulation of tumor suppressor genes ([@B88]). In recent years, more HDAC inhibitors have been approved by FDA such as romidepsin and vorinostat ([@B109]). Most of the inhibitors used in clinic are not effective in the treatment of solid tumors, and they are also limited in the treatment of hematological malignant tumors ([@B166]). Recent studies showed that HDAC inhibitors cooperated with MDM2 inhibitors to suppress the proliferation of tumor cells ([@B117]). Inhibition of HDAC not only lead to the accumulation of activated p53, but also modified the hyperacetylation of p53 to enhance the anti-tumor activity of MDM2 inhibitors ([@B192]; [@B117]). He et al. designed and synthesized the first MDM2/HDAC dual inhibitor according to the known binding model of MDM2 and HDAC inhibitors. These synthetic compounds showed excellent targeted inhibitory effects on HDAC and MDM2 in analysis of biochemical evaluation and structure-activity relationship as well as good anti-tumor activity in the xenograft model of A549 *in vivo* ([@B71]). These studies suggest that inhibitors targeting both HDAC and MDM2 may be a new way to treat cancer.

### Dual Inhibitors of MDM2 and TSPO {#s6_2_3}

The translocation protein (TSPO) is an 18 kDa transmembrane protein, which mainly exists in the outer membrane of mitochondria and constitutes a key part of the mitochondrial permeability transition pore (MPTP) ([@B8]). MPTP could affect apoptosis by regulating mitochondrial outer membrane permeabilization (MOMP) ([@B163]), suggesting TSPO as a useful target to trigger cellular apoptosis ([@B31]). Welsch.et al confirmed that multi-target single molecules of TSPO and MDM2 would enhance the antitumor efficacy ([@B186]). A 2-phenylindolylglyoxylyl dipeptide was designed to bind TSPO, leading to the disruption of MDM2-p53 interaction, cell-cycle arrest, and apoptosis in human GBM cells ([@B39]).

### Dual Inhibitors of MDM2 and XIAP {#s6_2_4}

XIAP belongs to IAP family, which can down-regulate the mitochondrial apoptosis by inhibiting caspase3, 7, and 9. XIAP is highly expressed in various types of cancer and is related to poor outcome ([@B165]; [@B11]; [@B125]). The binding between IRES region of XIAP and MDM2 induced translation enhancement of XIAP and stability of MDM2 ([@B26]; [@B99]). Zhou et al. developed a protein-RNA fluorescence polarization (FP) assay for high-throughput screening (HTS) of chemical libraries and identified eight inhibitors blocking the MDM2 protein-XIAP RNA interaction. The compound-induced MDM2 downregulation resulted in inhibition of XIAP expression and in activation of p53, which contributed to cell apoptosis and proliferation inhibition ([@B68]).

### Dual Inhibitors of MDM2 and Integrins {#s6_2_5}

Fibronectin is a gene cluster related to highly malignant glioblastoma and includes main receptors α5β1, αvβ6, αvβ8, and αvβ3 integrins ([@B45]; [@B110]). A selective antagonist of integrin receptors perturbed α5β1 function, provoked cell cycle arrest and decreased cell aggressiveness ([@B107]). An effective α5β1/αvβ3 integrin binding agent was identified to inhibit MDM2/4 activity and reactivated p53 pathway. In addition, this compound can induce cell cycle arrest, reduce the invasiveness of GBM cells and block the proliferation of p53 wild-type GBM cells ([@B122]). The novel class of integrin/MDM2 inhibitors is useful in the subpopulation of patients with glioblastoma expressing functional p53 concomitantly with a high level of α5β1 integrin ([@B122]).

Conclusion {#s7}
==========

Genotoxic attacks are a huge threat to genomic stability. With the major role of p53 in maintaining genome integrity, it is a big challenge to dissect out diverse regulatory roles of p53. Since the first identification of MDM2 cDNA repeats in transformed mouse 3T3 cells, evidence has increasing supported the functions of MDM2 in regulating cell proliferation, senescence, DNA repair, and apoptosis through p53-dependent and p53-independent pathways. MDM2 forms a large protein interactome to participate in different signal pathways, with the consideration of its changed protein conformations, modulated protein isoforms, tightly regulated post-translational modifications and subcellular localization. MDM2 keeps p53 content to a basal level in normal conditions. In response to stress signals like DNA damage, both MDM2 and p53 undergo diverse post-translational modifications, resulting in p53 stability and activation to regulate target genes transcription. One of the strategies for drug discovery is to improve p53 activity by inhibiting MDM2-p53 interaction. Further studies are needed to clarify the cell fate determination by MDM2-p53 axis after DNA damage and other regulatory pathways of MDM2 protein, especially the diverse isoforms of MDM2 in DNA repair process.
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